GSK China fined record-high $500m for bribery   

葛兰素史克(中国)被罚30亿元 系迄今中国最大罚单

湖南省长沙市中级人民法院19日依法对葛兰素史克(中国)投资有限公司(简称GSKCI)和马克锐等人对非国家工作人员行贿、非国家工作人员受贿案进行不公开开庭审理，并于当日公开宣判。GSKCI被判处罚金人民币30亿元，这是迄今为止中国开出的最大罚单，马克锐等被告人被判处有期徒刑二到四年。[查看全文]

(ECNS) -- GlaxoSmithKline (GSK) China was fined 3 billion yuan (about $500 million) for bribery.

Changsha Intermediate People's court in Hunan province ruled on Friday, September 19 that the company was guilty of bribing non-governmental personnel for improper commercial gains.

GSK China's general manager Mark Reilly and other people involved in the case were sentenced to two to four years' imprisonment.

The British drugmaker was found offering bribes to hospitals, doctors, other medical institutions and organizations for billions of yuan in illegal profit, inflating drug prices.

This is the biggest penalty China has imposed on a company.

GSK posted an apology on its official website after the verdict was read.